Stay updated on VRDN 001 Safety and Efficacy in TED Clinical Trial
Sign up to get notified when there's something new on the VRDN 001 Safety and Efficacy in TED Clinical Trial page.

Latest updates to the VRDN 001 Safety and Efficacy in TED Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2, and the Back to Top element has been removed. These changes are minor and do not affect core content or functionality.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations, as well as detailed information on nicotine chewing gum and related therapeutic categories. The revision number has also been updated to v3.0.0.SummaryDifference5%
- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated to include a new clinical trial for the investigational drug veligrotug (VRDN-001) for treating thyroid eye disease, along with detailed information about the study's objectives, eligibility criteria, and locations. Some redundant content and error messages have been removed.SummaryDifference100%
Stay in the know with updates to VRDN 001 Safety and Efficacy in TED Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VRDN 001 Safety and Efficacy in TED Clinical Trial page.